Literature DB >> 1964181

Basic fibroblast growth factor: a potential autocrine regulator of human glioma cell growth.

J L Gross1, R S Morrison, K Eidsvoog, W F Herblin, P L Kornblith, D L Dexter.   

Abstract

Basic fibroblast growth factor (bFGF) is a potent mitogen and angiogenic factor. bFGF is expressed by a variety of solid human tumors and has been implicated as an autocrine regulator of tumor growth. Different solid tumor lines including glioma, colon carcinoma and melanoma were examined for intracellular immunoreactive bFGF, high- and low-affinity bFGF receptors and mitogenic response to bFGF when grown in chemically defined medium. All tumor lines contained significant levels of bFGF. In addition, all tumor lines contained subsets of five forms of immunoreactive bFGF, as well as 0.68-20 x 10(6) low affinity bFGF binding sites (Kd = 15-300 nM). Most, but not all lines exhibited high affinity bFGF receptors (Kd = 25-40 pM). Glioma cell lines were distinguished by expressing the highest levels of bFGF protein as well as the most high-affinity receptors for bFGF. Furthermore, glioma cell lines were the only tumor type mitogenically responsive to bFGF. These results indicate that glioma cells express high levels of this potent mitogen and angiogenic factor relative to human colon carcinoma and melanoma cells. The expression of bFGF and bFGF receptors by glioma cells may be related to abnormal growth and neoplastic progression in these tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964181     DOI: 10.1002/jnr.490270429

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  11 in total

1.  Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells.

Authors:  Gui Su; Kristy Meyer; Chilkunda D Nandini; Dianhua Qiao; Shahriar Salamat; Andreas Friedl
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

2.  The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro.

Authors:  I F Pollack; S Kawecki
Journal:  J Neurooncol       Date:  1997-02       Impact factor: 4.130

3.  The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis.

Authors:  G Barillari; L Albonici; O Franzese; A Modesti; F Liberati; P Barillari; B Ensoli; V Manzari; G Santeusanio
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 4.  C6 cell line: the gold standard in glioma research.

Authors:  D Giakoumettis; A Kritis; N Foroglou
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

Review 5.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

Review 6.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

7.  Suramin inhibits glioma cell proliferation in vitro and in the brain.

Authors:  S Takano; S Gately; H Engelhard; A M Tsanaclis; S Brem
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells.

Authors:  T Ueba; T Nosaka; J A Takahashi; F Shibata; R Z Florkiewicz; B Vogelstein; Y Oda; H Kikuchi; M Hatanaka
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

9.  Morphologic, immunologic, biochemical, and cytogenetic characteristics of the human glioblastoma-derived cell line, SNB-19.

Authors:  W C Welch; R S Morrison; J L Gross; S M Gollin; R B Kitson; R H Goldfarb; K A Giuliano; M K Bradley; P L Kornblith
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-09       Impact factor: 2.416

10.  In vitro growth suppression of human glioma cells by a 16-mer oligopeptide: a potential new treatment modality for malignant glioma.

Authors:  Katsuhiko Kono; Tetsuya Ueba; Jun A Takahashi; Nozomu Murai; Nobuo Hashimoto; Akira Myoumoto; Nobuo Itoh; Manabu Fukumoto
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.